Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics
Merck-Wellcome Joint Venture to Manufacture Experimental Ebola Vaccine for Congo Outbreak
00

Merck-Wellcome Joint Venture to Manufacture Experimental Ebola Vaccine for Congo Outbreak

Jul 30, 2026

As a fast-spreading Bundibugyo Ebola outbreak in the Democratic Republic of Congo claims 1,487 lives, Hilleman Laboratories—a Merck-Wellcome joint venture—partners with the International AIDS Vaccine Initiative to manufacture an experimental vaccine. Backed by $8.5 million from CEPI, the effort leverages Merck's technical expertise to prepare clinical trial doses by late 2026, while parallel trials evaluate therapeutic drugs.

Bundibugyo Ebola outbreak in Congo

  • ▪The Ebola outbreak in the eastern Democratic Republic of Congo is caused by the rare Bundibugyo strain, for which there are no approved vaccines or treatments.
  • ▪An Ebola outbreak in the eastern Democratic Republic of Congo has infected 3,360 people and killed 1,487 as of July 29, 2026.

Hilleman-IAVI vaccine manufacturing effort

  • ▪Hilleman Laboratories, a Singapore-based joint venture between Merck and Wellcome, is preparing to manufacture doses of an experimental Bundibugyo Ebola vaccine developed by the International AIDS Vaccine Initiative.
  • ▪Hilleman Laboratories will use starting material from the International AIDS Vaccine Initiative to produce finished vaccine doses for early-stage clinical trials, which could be ready by the end of 2026.

CEPI funding for vaccine candidates

  • ▪The Coalition for Epidemic Preparedness Innovations committed up to $50 million to develop a Bundibugyo Ebola vaccine candidate with Moderna.
  • ▪The Coalition for Epidemic Preparedness Innovations is funding a separate Bundibugyo vaccine candidate from the University of Oxford with up to $8.6 million.
  • ▪The Coalition for Epidemic Preparedness Innovations is providing up to $8.5 million in funding to support the Hilleman Laboratories vaccine manufacturing effort.

Merck rVSV platform technical expertise

  • ▪Merck will serve as a technical adviser, contributing scientific and manufacturing expertise on the recombinant vesicular stomatitis virus platform to Hilleman Laboratories.
  • ▪The experimental International AIDS Vaccine Initiative vaccine uses the recombinant vesicular stomatitis virus platform, which is the same platform used for Merck's approved Ervebo vaccine.
  • ▪Merck and the Coalition for Epidemic Preparedness Innovations partnered earlier in 2026 on a $30 million program to update the manufacturing processes of the Ervebo vaccine.

Treatment trials for Bundibugyo Ebola

  • ▪Clinical trials are underway testing Mapp Biopharmaceuticals' pan-Ebola virus antibody drug MBP134 and Gilead Sciences' antiviral remdesivir, both alone and in combination.

Antibody therapies under WHO consideration

  • ▪The World Health Organization is considering clinical trials of Regeneron's antibody drug maftivimab in combination with two other antibodies, alongside Gilead Sciences' oral antiviral drug obeldesivir.

1 source

Reuters
Merck, Wellcome partner with global health group to make Ebola vaccine for clinical trials | Reuters
View source article

Featured stories

First Volunteer Vaccinated in World’s First Bundibugyo Ebola Vaccine Trial

Jul 24, 2026 · 4 sources

Story comments

Loading comments…

Related Projects

Merck

Topics

PharmaEbola outbreakVaccines and Immunization PolicyVaccine developmentOutbreak-Driven VaccinationInfectious Disease and OutbreaksVaccine development and innovation

Featured stories

First Volunteer Vaccinated in World’s First Bundibugyo Ebola Vaccine Trial

Jul 24, 2026 · 4 sources